Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells 8,000 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the transaction, the chief executive officer now owns 2,079,128 shares in the company, valued at approximately $156,558,338.40. The sale was disclosed in a legal filing with the SEC, which is available through this link.

LeMaitre Vascular Stock Up 1.3 %

Shares of LeMaitre Vascular stock opened at $76.00 on Friday. The business has a fifty day simple moving average of $66.67 and a 200-day simple moving average of $59.46. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $76.24. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 50.33, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. LeMaitre Vascular’s revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.27 earnings per share. Analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be paid a $0.16 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.84%. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. KeyCorp initiated coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating on the stock. JMP Securities lifted their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday, May 3rd. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Barrington Research raised their price target on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their price target for the company from $59.00 to $75.00 in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $73.83.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently modified their holdings of the stock. Shaker Investments LLC OH grew its stake in LeMaitre Vascular by 1.3% in the first quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 169 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of LeMaitre Vascular by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock valued at $1,343,000 after buying an additional 187 shares in the last quarter. Riverwater Partners LLC increased its holdings in LeMaitre Vascular by 2.5% in the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after buying an additional 198 shares during the last quarter. Albion Financial Group UT raised its position in LeMaitre Vascular by 5.6% during the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock valued at $264,000 after acquiring an additional 212 shares in the last quarter. Finally, Texas Permanent School Fund Corp lifted its stake in LeMaitre Vascular by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after acquiring an additional 225 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.